China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its antibody-drug conjugate (ADC) BL-M11D1 targeting CD33. The study will evaluate the drug in combination with cytarabine plus daunorubicin or venetoclax plus azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML).
Clinical Trial and Development
BL-M11D1 is currently undergoing a Phase Ib study in China and a Phase I study in the US for the treatment of recurrent or refractory AML. This dual-track approach highlights the company’s commitment to advancing therapeutic options for patients with this aggressive form of leukemia.-Fineline Info & Tech
